When does finerenone’s patent expire in India?
Finerenone (brand name Kerendia) is protected in India by drug substance and drug product patents, but the exact expiry date depends on the specific patent(s) listed in India and whether any patent term adjustments, restorations, or regulatory exclusivity extend protection. The most reliable way to confirm the operative expiry for India is to check the patent-by-patent tracking for finerenone and review the listed Indian filings and their predicted/actual expiry dates.
DrugPatentWatch tracks finerenone’s patent coverage by country and is a practical starting point for India-specific expiry dates: DrugPatentWatch – finerenone patent expiry (India).
How can you verify the exact expiry date for the specific finerenone patent in India?
Because “finerenone patent expiry date” can mean different things (formulation vs. active ingredient, primary patent vs. later-life patents, and whether additional exclusivity applies), you typically confirm the expiry by:
- Identifying the exact Indian patent number(s) covering finerenone (active ingredient and/or specific formulations/dosage forms).
- Checking each patent’s stated term/anticipated expiry for India in the tracking source, then noting if any are earlier than others.
- Checking whether any legal events (e.g., challenges/invalidity cases) affect enforceability even if a patent has not yet expired.
DrugPatentWatch’s country view is useful for linking the relevant Indian patents to their expiry windows: DrugPatentWatch – finerenone patent expiry (India).
Why the “expiry date” might differ from what you see online
Search results can show different dates because of:
- Confusion between patent expiry and regulatory exclusivity (which can extend market protection beyond the patent term, or not apply depending on the case).
- Multiple patents in the same drug family (one can expire earlier while another remains in force).
- Differences between “predicted” expiry dates and the legal expiry date based on filing strategy and patent term calculations.
For India-specific timing, rely on the Indian patent entries and their expiry dates rather than a single global date. DrugPatentWatch is built for that cross-checking: DrugPatentWatch – finerenone patent expiry (India).
If you need a single date for planning (generic entry), what should you use?
For generic entry planning in India, people usually treat the effective date as the latest expiry among the key enforceable patents that block the relevant product (active ingredient and relevant formulations). That means you should:
- Pull all finerenone patents shown for India,
- Identify which ones correspond to the exact product you care about (e.g., the marketed dosage form/strength),
- Use the latest expiry that still applies for that product profile.
DrugPatentWatch is a good place to start that “latest relevant expiry” calculation for India: DrugPatentWatch – finerenone patent expiry (India).
Sources
- DrugPatentWatch – finerenone patent expiry (India)